We hope you find what you’re looking for. You can email us if you need additional help.
Forbes Australia covered Optimi co-founder, JJ Wilson’s, journey toward making Optimi the number one supplier of psilocybin and MDMA in Australia. Read the article here.
The Financial Review Australia full article can be found here.
Canada has licensed a startup to export psychedelics to Australia for patient use, the latest milestone in a contest to supply the potential growth of medical psychedelic drugs. Full story here.
(Bloomberg) — Canada has licensed a startup to export psychedelics to Australia for patient use, the latest milestone in a contest to supply the potential growth of medical psychedelic drugs. Full story here.
By Trevor Abes Optimi Health (CSE:OPTI), a microcap psychedelics manufacturer, has been awarded a Drug Establishment Licence from Health Canada to produce and sell its MDMA and psilocybin capsules to an Australian client. The designation certifies that the Vancouver-based company
By Rowan Dunne British Columbia’s psychedelics and natural health products company Optimi Health Corp. (CSE: OPTI) has been making significant progress toward achieving its international distribution goals. This week, the company obtained a permit to send MDMA and psilocybin capsules
Correction Notice: We wish to correct an inaccuracy reported yesterday in the following article published in The Australian, which claimed that Optimi Health has been granted a “permit to export” MDMA and psilocybin capsules. At this time, Optimi Health has
Story written by Stockhouse Optimi Health (CSE:OPTI) has signed a letter of intent with ATMA Journey Centers to advance its psilocybin extract into ATMA’s Phase II Psilocybin Clinical trial to treat major depressive disorder (MDD). While a definitive agreement will
Optimi Health (CSE:OPTI) revealed it has made its first international shipment of MDMA to The Institute for Psychedelic Research at Tel Aviv University. The company stated in a news release it obtained an export permit that is required from Health
Optimi Health Corp (CSE:OPTI, OTCQB:OPTHF) announced it received a Certificate of Analysis from an independent, third-party laboratory testing that confirms its formulated MDMA meets Good Manufacturing Practice (GMP) specifications. The company said on Tuesday it had also completed GMP process
Regulator Filings
Legal Counsel: Norton Rose Fulbright
Auditor: Smythe CPA
Transfer Agent: Endeavor Trust
Corporate Visibility & Investor Relations: Kydder Group
Trading Symbol: CSE: OPTI | OTC:OPTHF |
FRA: 8BN
CUSIP Number: 68405H100
ISIN Number: CA68405H1001
WKN: A2QQEL
Issued & Outstanding: (30/06/2022) 80,451,883
Incorporated: BC / May 27, 2020
Year End: September 30th
